Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. develops medical technology for ambulatory cardiac monitoring, centered on a patented cable-free 3D ECG platform that captures signals from three non-coplanar dimensions and synthesizes a 12-lead ECG. News commonly covers the FDA-cleared HeartBeam System for arrhythmia assessment, limited commercial launch activity, preventive cardiology and concierge practice deployments, AI-ECG collaboration, and development of on-demand patch and heart attack detection initiatives.
Corporate updates also include financial results and common-stock financing used to support commercialization, product development, AI capabilities, working capital, and general corporate purposes.
HeartBeam, Inc. (NASDAQ: BEAT) has priced its initial public offering of 2,750,000 units at $6.00 per unit, consisting of one share of common stock and one warrant. The offering is expected to generate $16.5 million in gross proceeds, aimed at funding product development and regulatory work for its ECG telemedicine technology. The company anticipates trading to begin on November 11, 2021, with a closing date set for November 15, 2021. The underwriters have a 30-day option to purchase additional shares.
Philips has announced its acquisition of BioTelemetry for USD 72.00 per share, totaling an implied enterprise value of USD 2.8 billion. This acquisition aligns with Philips' strategy to enhance healthcare delivery by combining its hospital monitoring capabilities with BioTelemetry’s strengths in remote cardiac diagnostics. BioTelemetry, which reported USD 439 million in sales in 2019, monitors over 1 million cardiac patients annually. The deal is anticipated to yield significant synergies and is expected to be accretive to Philips’ sales growth and adjusted EBITA margin beginning in 2021.
BioTelemetry, Inc. (NASDAQ:BEAT) reported a record quarterly revenue of $114.7 million for Q3 2020, marking a 3.0% year-over-year growth despite COVID-19 challenges. The company achieved a GAAP net income of $6.7 million (or $0.18 per diluted share), down from $8.3 million in Q3 2019. Adjusted net income was $16.5 million ($0.45 per diluted share). The gross profit was $69.0 million, representing 60.2% of total revenue. CEO Joseph H. Capper highlighted growth in all business segments and projected over 15% top-line growth in 2021.
BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2020 earnings on October 29 at 4:00 PM ET. Following this, an earnings conference call will take place at 5:00 PM ET, which will be available via webcast on the investor relations page of their website.
BioTelemetry specializes in remote medical technology, offering services that enhance health information accessibility and lower care costs. Their solutions include remote cardiac monitoring and clinical trial laboratory services.
BioTelemetry, Inc. (NASDAQ: BEAT) has acquired the On.Demand™ remote patient monitoring platform from Envolve People Care, a subsidiary of Centene Corporation. This acquisition enhances BioTelemetry's offerings for chronic care management, specifically targeting diabetes, hypertension, and chronic heart failure. The deal establishes BioTelemetry as the exclusive provider of diabetes RPM services to Centene's Medicaid members. The On.Demand platform aims to improve patient engagement and compliance while reducing healthcare costs through real-time monitoring and coaching.
BioTelemetry, Inc. (NASDAQ: BEAT) will announce its second quarter 2020 earnings on July 30 at 4:00 PM ET, followed by a conference call at 5:00 PM ET. The call will be accessible via the investor section of the BioTelemetry website. The company, a leader in remote medical technology, offers services including remote cardiac monitoring and centralized laboratory services for clinical trials. This announcement may set expectations for the company’s financial performance ahead of the earnings release.
Summary not available.
Summary not available.